Basic and translational research on proteinase-activated receptors: The role of thrombin receptor in cerebral vasospasm in subarachnoid hemorrhage

Journal of Pharmacological Sciences

Volumn 108, Issue 4, 2008, Pages 426-432

  Kai, Yasutoshi ^a   Maeda, Yoshihisa ^a   Sasaki, Tomio ^a   Kanaide, Hideo ^a,b   Hirano, Katsuya ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Antagonist; Cerebral vasospasm; Proteinase activated receptor 1 (PAR1); Subarachnoid hemorrhage; Thrombin

Indexed keywords

E 5555; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 BLOCKING AGENT; RECEPTOR BLOCKING AGENT; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BASILAR ARTERY; BLOOD VESSEL REACTIVITY; BRAIN VASOSPASM; CONFERENCE PAPER; CONTROLLED STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SUBARACHNOID HEMORRHAGE;

EID: 58149154839     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R11FM     Document Type: Conference Paper

References (68)

1. Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985;16:562-572.
2. Dorsch NW. The effect and management of delayed vasospasm after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 1998;38 Suppl:156-160.
3. Sasaki T, Kassell NF, Yamashita M, Fujiwara S, Zuccarello M. Barrier disruption in the major cerebral arteries following experimental subarachnoid hemorrhage. J Neurosurg. 1985;63:433-440.
4. Johshita H, Kassell NF, Sasaki T. Blood-brain barrier disturbance following subarachnoid hemorrhage in rabbits. Stroke. 1990;21:1051-1058.
5. Pluta RM. Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Neurol Res. 2006;28:730-737.
6. Sasaki T, Wakai S, Asano T, Watanabe T, Kirino T, Sano K. The effect of a lipid hydroperoxide of arachidonic acid on the canine basilar artery. An experimental study on cerebral vasospasm. J Neurosurg. 1981;54:357-365.
7. Sato M, Tani E, Fujikawa H, Kaibuchi K. Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res. 2000;87:195-200.
8. Miyagi Y, Carpenter RC, Meguro T, Parent AD, Zhang JH. Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg. 2000;93:471-476.
9. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:1-9.
10. Kasuya H, Shimizu T, Takakura K. Thrombin activity in CSF after SAH is correlated with the degree of SAH, the persistence of subarachnoid clot and the development of vasospasm. Acta Neurochir (Wien). 1998;140:579-584.
11. Suzuki M, Kudo A, Otawara Y, Hirashima Y, Takaku A, Ogawa A. Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. Neurosurgery. 1999;44:487-493.
12. Tsurutani H, Ohkuma H, Suzuki S. Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. Stroke. 2003;34:1497-1500.
13. Saito I, Ueda Y, Sano K. Significance of vasospasm in the treatment of ruptured intracranial aneurysms. J Neurosurg. 1977;47:412-429.
14. Sano K, Saito I. Timing and indication of surgery for ruptured intracranial aneurysms with regard to cerebral vasospasm. Acta Neurochir (Wien). 1978;41:49-60.
15. Inagawa T, Yamamoto M, Kamiya K. Effect of clot removal on cerebral vasospasm. J Neurosurg. 1990;72:224-230.
16. Yoshida Y, Hayashi T, Amoh M, Ahagon A, Kusuno K, Uno T, et al. Postoperative intrathecal irrigation with plasminogen activator (Urokinase) after early stage operation on ruptured cerebral aneurysm. Neurol Med Chir (Tokyo). 1983;23:659-666.
17. Findlay JM, Weir BK, Kassell NF, Disney LB, Grace MG. Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage. J Neurosurg. 1991;75:181-188.
18. Sasaki T, Ohta T, Kikuchi H, Takakura K, Usui M, Ohnishi H, et al. A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1994;35:597-604.
19. Kosnik EJ, Hunt WE. Postoperative hypertension in the management of patients with intracranial arterial aneurysms. J Neurosurg. 1976;45:148-154.
20. Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000;31:383-391.
21. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, et al. Cerebral arterial spasm: a controlled trial of nimodipine in patients with subarachnoid hemorrhage. New Engl J Med. 1983;308:619-624.
22. Gaab MR, Czech T, Korn A. Intracranial effects of nicardipine. Br J Clin Pharmacol. 1985;20 Suppl 1:67S-74S.
23. Takayasu M, Suzuki Y, Shibuya M, Asano T, Kanamori M, Okada T, et al. The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs. J Neurosurg. 1986;65:80-85.
24. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 1992;76:571-577.
25. Sasaki T, Wakai S, Asano T, Takakura K, Sano K. Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581. J Neurosurg. 1982;57:74-82.
26. Suzuki S, Sano K, Handa H, Asano T, Tamura A, Yonekawa Y, et al. Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. Neurol Res. 1989;11:79-88.
27. McGirt MJ, Lynch JR, Parra A, Sheng H, Pearlstein RD, Laskowitz DT, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke. 2002;33:2950-2956.
28. Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke. 2005;36:1627-1632.
29. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther. 1997;283:1110-1118.
30. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg. 2005;103:9-17.
31. Zubkov YN, Nikiforov BM, Shustin VA. Balloon catheter technique for dilatation of constricted cerebral arteries after aneurysmal SAH. Acta Neurochir (Wien). 1984;70:65-79.
32. Kaku Y, Yonekawa Y, Tsukahara T, Kazekawa K. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 1992;77:842-847.
33. Kassell NF, Helm G, Simmons N, Phillips CD, Cail WS. Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg. 1992;77:848-852.
34. Tachibana E, Harada T, Shibuya M, Saito K, Takayasu M, Suzuki Y, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien). 1999;141:13-19.
35. White RP, Hagen AA, Morgan H, Dawson WN, Robertson JT. Experimental study on the genesis of cerebral vasospasm. Stroke. 1975;6:52-57.
36. White RP, Chapleau CE, Dugdale M, Robertson JT. Cerebral arterial contractions induced by human and bovine thrombin. Stroke. 1980;11:363-368.
37. Hirano K, Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb. 2003;10:211-225.
38. 4) in Vascular Endothelial Cells. J Pharmacol Exp Ther. 2007;322:668-677.
39. McLaughlin JN, Patterson MM, Malik AB. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci U S A. 2007;104:5662-5667.
40. Hollenberg MD. Physiology and pathophysiology of proteinase-activated receptors (PARs): proteinases as hormone-like signal messengers: PARs and more. J Pharmacol Sci. 2005;97:8-13.
41. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27:27-36.
42. Maeda Y, Hirano K, Kai Y, Hirano M, Suzuki SO, Sasaki T, et al. Up-regulation of proteinase-activated receptor 1 and increased contractile responses to thrombin after subarachnoid haemorrhage. Br J Pharmacol. 2007;152:1131-1139.
43. Kai Y, Hirano K, Maeda Y, Nishimura J, Sasaki T, Kanaide H. Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke. 2007;38:3259-3265.
44. Muramatsu I, Laniyonu A, Moore GJ, Hollenberg MD. Vascular actions of thrombin receptor peptide. Can J Physiol Pharmacol. 1992;70:996-1003.
45. Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol. 1993;22:609-616.
46. Godin D, Rioux F, Marceau F, Drapeau G. Mode of action of thrombin in the rabbit aorta. Br J Pharmacol. 1995;115:903-908.
47. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90:1614-1621.
48. Hirano K, Yufu T, Hirano M, Nishimura J, Kanaide H. Physiology and pathophysiology of proteinase-activated receptors (PARs): regulation of the expression of PARs. J Pharmacol Sci. 2005;97:31-37.
49. Svendgaard NA, Edvinsson L, Owman C, Sahlin C. Increased sensitivity of the basilar artery to norepinephrine and 5-hydroxytryptamine following experimental subarachnoid hemorrhage. Surg Neurol. 1977;8:191-195.
50. Hara H, Edvinsson L. Perivascular innervation of the cerebral circulation: involvement in the pathophysiology of subarachnoid hemorrhage. Neurosurg Rev. 1987;10:171-179.
51. Zhang H, Weir BK, Macdonald RL, Marton LS, Solenski NJ, Kwan AL, et al. Mechanisms of [Ca++]i elevation induced by erythrocyte components in endothelial cells. J Pharmacol Exp Ther. 1996;277:1501-1509.
52. Asano T. Oxyhemoglobin as the principal cause of cerebral vasospasm: a holistic view of its actions. Crit Rev Neurosurg. 1999;9:303-318.
53. Macdonald RL, Weir BK. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke. 1991;22:971-982.
54. Tanishima T. Cerebral vasospasm: contractile activity of hemoglobin in isolated canine basilar arteries. J Neurosurg. 1980;53:787-793.
55. Ito M. Experimental vasospasms-significance of oxyhemoglobin, fibrin degradation products and breakdown products of white ghost in the pathogenesis of cerebral vasospasms. Treatment of vasospasms with gabexate mesilate and diphenhydramine. Neurol Med Chir (Tokyo). 1980;20:225-236.
56. Forster C, Whalley ET, Mohan J, Dutton J. Vascular smooth muscle response to fibrinogen degradation products and 5-hydroxytryptamine: possible role in cerebral vasospasm in man. Br J Clin Pharmacol. 1980;10:231-236.
57. Allen GS, Henderson LM, Chou SN, French LA. Cerebral arterial spasm. 1. In vitro contractile activity of vasoactive agents on canine basilar and middle cerebral arteries. J Neurosurg. 1974;40:433-441.
58. Kapp J, Mahaley MS Jr, Odom GL. Cerebral arterial spasm. 2. Experimental evaluation of mechanical and humoral factors in pathogenesis. J Neurosurg. 1968;29:339-349.
59. Ellis EF, Nies AS, Oates JA. Cerebral arterial smooth muscle contraction by thromboxane A2. Stroke. 1977;8:480-483.
60. Gaetani P, Tancioni F, Grignani G, Tartara F, Merlo EM, Brocchieri A, et al. Platelet derived growth factor and subarachnoid haemorrhage: a study on cisternal cerebrospinal fluid. Acta Neurochir (Wien). 1997;139:319-324.
61. La Torre E, Patrono C, Fortuna A, Grossi-Belloni D. Role of prostaglandin F2 in human cerebral vasospasm. J Neurosurg. 1974;41:293-299.
62. Hagen AA, Gerber JN, Sweeley CC, White RP, Robertson JT. Levels and disappearance of prostaglandin F2alpha in cerebral spinal fluid: a clinical and experimental study. Stroke. 1977;8:672-675.
63. Walker V, Pickard JD, Smythe P, Eastwood S, Perry S. Effects of subarachnoid haemorrhage on intracranial prostaglandins. J Neurol Neurosurg Psychiatry. 1983;46:119-125.
64. Tosaka M, Okajima F, Hashiba Y, Saito N, Nagano T, Watanabe T, et al. Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke. 2001;32:2913-2919.
65. Boullin DJ, Bunting S, Blaso WP, Hunt TM, Moncada S. Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: their relevance to cerebral arterial spasm in man. Br J Clin Pharmacol. 1979;7:139-147.
66. A receptor antagonist, BQ-485, and its preventive effect on experimental cerebral vasospasm in dogs. Biochem Biophys Res Commun. 1993;195:969-975.
67. Ide K, Yamakawa K, Nakagomi T, Sasaki T, Saito I, Kurihara H, et al. The role of endothelin in the pathogenesis of vasospasm following subarachnoid haemorrhage. Neurol Res. 1989;11:101-104.
68. Maeda Y, Hirano K, Hirano M, Kikkawa Y, Kameda K, Sasaki T, et al. Enhanced contractile response of the basilar artery to platelet-derived growth factor in subarachnoid hemorrhage. Stroke. In press 2009.